ROIV – Roivant Sciences Ltd

Roivant Sciences Ltd.

ROIV

$41.85

Name : Roivant Sciences Ltd.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $30,322,896,896.00

EPSttm : -0.65

Roivant Sciences Ltd.

$41.85

1.60%

$0.66

ROIV — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

8.68

Margin Of Safety %

Put/Call OI Ratio

0.47

EPS Next Q Diff

-0.11

EPS Last/This Y

-1.13

EPS This/Next Y

0.16

Price

41.85

Target Price

50.64

Analyst Recom

1.4

Performance Q

15.35

Upside

-117.4%

Beta

1.19

Ticker: ROIV

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-13	ROIV	33.37	0.46	0.32	80716
2026-10-14	ROIV	33.62	0.46	0.07	80723
2026-10-15	ROIV	34.04	0.46	0.80	80709
2026-10-16	ROIV	33.52	0.46	0.10	80719
2026-10-19	ROIV	34.68	0.46	0.22	79712
2026-10-20	ROIV	34.92	0.46	0.13	79719
2026-10-21	ROIV	36.81	0.46	0.85	79757
2026-10-22	ROIV	37.44	0.48	0.00	81934
2026-10-23	ROIV	36.53	0.48	0.04	81831
2026-10-26	ROIV	36.06	0.48	0.33	81839
2026-10-27	ROIV	36.57	0.48	0.33	81820
2026-10-28	ROIV	37.1	0.48	0.92	81834
2026-10-29	ROIV	37.51	0.48	0.00	81941
2026-10-30	ROIV	36.86	0.48	1.34	81881
2026-11-02	ROIV	35.9	0.48	0.00	82010
2026-11-03	ROIV	36.06	0.48	0.70	82014
2026-11-04	ROIV	38.22	0.48	0.00	82030
2026-11-05	ROIV	36.61	0.48	0.47	82418
2026-11-06	ROIV	38.89	0.48	0.06	82447
2026-11-09	ROIV	40.67	0.48	0.02	82885
2026-11-10	ROIV	41.17	0.47	0.01	83131
2026-11-11	ROIV	41.85	0.47	0.00	83000
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-13	ROIV	33.36	-63.3	-	-1.58
2026-10-14	ROIV	33.62	-63.3	-	-1.58
2026-10-15	ROIV	34.05	-63.3	-	-1.58
2026-10-16	ROIV	33.52	-63.3	-	-1.58
2026-10-19	ROIV	34.71	-63.3	-	-1.58
2026-10-20	ROIV	34.71	-63.3	-	-1.58
2026-10-21	ROIV	34.93	-63.3	-	-1.58
2026-10-22	ROIV	37.44	-63.3	-	-1.58
2026-10-23	ROIV	36.49	-63.3	-	-1.58
2026-10-26	ROIV	36.06	-63.3	-	-1.58
2026-10-27	ROIV	36.57	-63.3	-	-1.58
2026-10-28	ROIV	37.10	-63.3	-	-1.58
2026-10-29	ROIV	37.50	-63.3	-	-1.58
2026-10-30	ROIV	36.91	-63.3	-	-1.58
2026-11-02	ROIV	35.89	-63.3	-	-1.58
2026-11-03	ROIV	36.06	-62.7	-	-1.56
2026-11-04	ROIV	38.22	-62.7	-	-1.56
2026-11-05	ROIV	36.63	-62.7	-	-1.56
2026-11-06	ROIV	38.92	-62.7	-	-1.56
2026-11-09	ROIV	40.67	-62.7	-	-1.56
2026-11-10	ROIV	41.17	-62.7	-	-1.56
2026-11-11	ROIV	41.85	-68.3	-	-1.56
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-13	ROIV	-3.92	3.89	7.50
2026-10-14	ROIV	-3.92	3.89	7.50
2026-10-15	ROIV	-3.92	3.89	7.50
2026-10-16	ROIV	-3.92	3.89	7.50
2026-10-19	ROIV	-3.92	3.89	7.50
2026-10-20	ROIV	-3.92	3.89	7.50
2026-10-21	ROIV	-3.78	3.89	7.50
2026-10-22	ROIV	-3.78	3.89	7.50
2026-10-23	ROIV	-3.78	3.89	7.50
2026-10-26	ROIV	-3.78	3.25	7.50
2026-10-27	ROIV	-3.78	3.25	7.69
2026-10-28	ROIV	-3.78	3.25	7.69
2026-10-29	ROIV	-3.78	3.25	7.69
2026-10-30	ROIV	-3.78	3.25	7.69
2026-11-02	ROIV	-3.88	4.47	7.69
2026-11-03	ROIV	-3.88	4.47	7.69
2026-11-05	ROIV	-3.88	4.47	7.69
2026-11-06	ROIV	-3.97	4.47	7.69
2026-11-09	ROIV	-3.97	2.79	7.69
2026-11-10	ROIV	-3.97	2.79	7.69
2026-11-11	ROIV	-3.97	2.79	8.68
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.3

Avg. EPS Est. Current Quarter

-0.4

Avg. EPS Est. Next Quarter

-0.41

Insider Transactions

-3.97

Institutional Transactions

2.79

Beta

1.19

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

1.5

Max Drawdown 5-Year %

-79.2

Target Price

50.64

P/E

Forward P/E

PEG

P/S

738.14

P/B

7.53

P/Free Cash Flow

EPS

-0.56

Average EPS Est. Cur. Y

-1.56

EPS Next Y. (Est.)

-1.39

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-876.58

Relative Volume

0.99

Return on Equity vs Sector %

-34.9

Return on Equity vs Industry %

-15.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

◆ ROIV Healthcare

$41.85

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

20/20

Pullback

6/25

Volume

7/15

Valuation

6/20

TP/AR

5/10

Options

7/10

RSI

Range 1M

97.3%

Sup Dist

3.8%

🚀

Momentum Growth

Ride accelerating trends

WATCH

Momentum

24/25

Growth

11/30

Estimates

6/20

Inst/Vol

8/15

Options

9/10

EPS Yr

-118%

EPS NY

3.1%

52W%

97.7%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟡 HOLD +21% upside

Quality

7/30

Valuation

6/30

Growth

8/25

Stability

7/10

LT Trend

4/5

Upside

+21%

Quality

ROIV — P/E HistoricalBiotechnology

Roivant Sciences Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 721

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

ROIV

Latest News

—

Caricamento notizie per ROIV…

stock quote shares ROIV – Roivant Sciences Ltd Stock Price stock today

news today ROIV – Roivant Sciences Ltd stock forecast ,stock prediction 2023 2024 2025

marketwatch ROIV – Roivant Sciences Ltd yahoo finance google finance

stock history ROIV – Roivant Sciences Ltd invest stock market

stock prices ROIV premarket after hours

ticker ROIV fair value insiders trading

ROIV – Roivant Sciences Ltd

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ROIV

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y